Effective inhibition of mitochondrial metabolism by Cryptotanshinone in MDA-MB231 cells : A Proteomic Analysis

Jiefeng Zhou, Qingcao Li, Haoran Wu, Shin-Han Tsai, Yu-Ting Yeh

Research output: Contribution to journalArticlepeer-review


Background Triple-negative breast cancer (TNBC) is a subtype of invasive cancer in breast with the symptoms of unfavourable prognosis and limited targeted treatment options. Evidence of changes in the metabolic status of TNBC, characterised by increased glycolysis, mitochondrial oxidative phosphorylation, as well as production and utilization of tricarboxylic acid cycle intermediates.

Objective Investigate the proteins altered in cryptotanshinone treated MDA-MB-231 cells and explore the key pathways and specific molecular markers involved in cryptotanshinone treatment.

Method We use unlabeled quantitative proteomics to gain insight into the anticancer mechanism of cryptotanshinone on MDA-MB231 triple negative breast cancer cells. And flow cytometry was used to detect apoptosis and changes in cell mitochondrial membrane potential.

Results We show that inhibiting the expression of electron transport chain complex proteins, also inhibits mitochondrial oxidative phosphorylation. Additionally, down-regulation of the ribosime biogenesis pathway was found to inhibit cell metabolism.

Conclusion In summary, results show that cryptotanshinone can trigger rapid and irreversible apoptosis in MDA-MB-231 cells through effectively inhibiting cell metabolism.
Original languageEnglish
Pages (from-to)20-29
JournalCurrent Proteomics
Issue number1
Publication statusPublished - Feb 2022


  • cryptotanshinone
  • proteomic
  • breast cancer
  • MDA-MB-231
  • mitochondrial


Dive into the research topics of 'Effective inhibition of mitochondrial metabolism by Cryptotanshinone in MDA-MB231 cells : A Proteomic Analysis'. Together they form a unique fingerprint.

Cite this